BioSpace News Archive

Waters has acquired technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry (CDMS).

Windtree Therapeutics, Inc. today announced it has completed enrollment in its Phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS).

Mydecine Innovations Group today announced in preparation for its FDA pre-Investigational New Drug (IND) meeting on February 28th, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (FDA) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program.

Sema4 today announced plans to strengthen its Market Access team to drive increased market access for the company’s platform.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of REDWOOD-HCM.

Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab.

Syneos Health will release its fourth quarter and full year 2021 financial results on Thursday, February 17th, 2022, prior to its earnings call at 8:00 a.m. ET.

The Barbara Ann Karmanos Cancer Institute was recently awarded a $50,000 lodging grant by the American Cancer Society to help eliminate the financial barriers of cancer treatment.

Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.

Numinus Wellness Inc. is pleased to announce the appointment of three key advisors to its new Bioscience Advisory Board.